Research Summary

Analyzed using Evidence Intelligence™

Semaglutide may reduce cardiovascular events in non-diabetic patients.

Key finding

The primary end point of first major adverse cardiovascular event (MACE) was reduced by 20% with semaglutide versus placebo.

The study evaluated the effects of semaglutide on cardiovascular events in individuals with overweight or obesity and established cardiovascular disease without diabetes, finding a 20% reduction in major adverse cardiovascular events.

Evidence strength

Moderate confidence

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Some Concerns bias

Last updated July 6, 2026

Quick read

Study at a glance

The essential study design details in one scan.

Population

Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes

Intervention

Semaglutide 2.4 mg

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Primary outcome

First major adverse cardiovascular event (MACE)

Comparator

Placebo

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

Clinical relevance

The findings are clinically significant as they suggest that semaglutide can be an effective intervention for reducing cardiovascular risks in a high-risk population. Given the increasing prevalence of obesity and related cardiovascular diseases, this treatment could help improve patient outcomes and reduce healthcare costs associated with cardiovascular events.

Keep in mind

The study's population may not be generalizable to all individuals with cardiovascular disease. Long-term effects of semaglutide on cardiovascular outcomes remain unclear. The trial did not include participants with diabetes, limiting applicability.

Published in

Journal Reference

Publication details and source links for this paper.

Ildiko L, John D, Steven EK, et al. Semaglutide Reduces Cardiovascular Events in Individuals with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes. Diabetes Care. 2024;47(8):1360-1369. doi:10.2337/dc24-0764

View DOI View on PubMed View on PMC

Save this study and add notes to your research library.

Main Effects

Semaglutide reduced the first major adverse cardiovascular event (MACE) by 20% compared to placebo.

Cardiovascular mortality risk reduction was consistent across baseline HbA1c groups.

Other cardiovascular outcomes, including nonfatal myocardial infarction and stroke, showed consistent trends across HbA1c subgroups.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Semaglutide and All-cause mortality, Cardiovascular events, Cardiovascular mortality, and 8 more.

This study contributes evidence to

Intervention

Semaglutide

Outcome

All-cause mortality

Evidence topic

Cardiovascular Risk

Primary intervention

Semaglutide

Primary outcomes

All-cause mortality
Cardiovascular events
Cardiovascular mortality

Evidence topics

Cardiovascular Risk GLP-1 Receptor Agonists

Primary intervention

Semaglutide

Primary outcomes

All-cause mortality Cardiovascular events Cardiovascular mortality

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 64

Why it is useful

Contributes to 11 evidence relationships
Includes primary outcome data
Linked to 2 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Semaglutide → Urgent medical visit for heart failure

Evidence profile

NoneNo ChangeClinical Outcomes

Unlock full evidence details

Unlock full evidence analysis

Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.

Evidence Suggest

Semaglutide showed a 20% decrease in major cardiovascular events.
No significant difference in cardiovascular mortality across HbA1c groups.
Consistent cardiovascular outcomes across various subgroups.

Who this applies to

Adults with overweight or obesity.
Individuals with established cardiovascular disease without diabetes.

Keep in Mind

Results may not apply to individuals with diabetes.
The study focused on a specific population, limiting broader applicability.
Further research is needed to confirm long-term effects.

Between the Lines

The study's population may not be generalizable to all individuals with cardiovascular disease.
Long-term effects of semaglutide on cardiovascular outcomes remain unclear.
The trial did not include participants with diabetes, limiting applicability.

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on GLP-1 Receptor Agonists and Cardiovascular Outcomes, GLP-1 Receptor Agonists and Cardiovascular Outcomes.

Related evidence relationships

Explore in Evidence Archive

This study contributes to the evidence on the following intervention-outcome relationships.

GLP-1 Receptor AgonistsCardiovascular Outcomes

Medications

3 studies

Detailed evidence

GLP-1 Receptor AgonistsCardiovascular Outcomes

Medications

5 studies

Detailed evidence

Included in these evidence collections

Curated evidence collections and hubs this study is part of.

Cardiovascular Outcomes Evidence Hub

All studies measuring Cardiovascular Outcomes

3 studies

outcome_hub

Measures Cardiovascular Outcomes as a key outcome.

GLP-1 Receptor Agonists Evidence Hub

All studies on GLP-1 Receptor Agonists

3 studies

intervention_hub

Contributes to GLP-1 Receptor Agonists evidence base.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Generated from the study's connected evidence using Evidence Intelligence™.

Does GLP-1 Receptor Agonists improve cardiovascular outcomes?

Emerging Evidence

GLP-1 Receptor Agonists may improve Cardiovascular Outcomes.

ConsensusScore™: Results are generally consistent across studies.

Ranked evidence signals

1
Cardiovascular events
EvidenceScore™ Moderate | EvidenceScore™ 60.6 | strong positive | ConsensusScore™ Consistent | 1 study
2
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Emerging | EvidenceScore™ 57.7 | moderate positive | ConsensusScore™ Generally Consistent | 1 study
3
All-cause mortality
EvidenceScore™ Emerging | EvidenceScore™ 54.4 | weak positive | ConsensusScore™ Mixed | 1 study

Why this answer: This answer is based on 9 supporting studies with generally consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does Semaglutide improve composite of cv death, non-fatal myocardial infarction, or non-fatal stroke?

Emerging Evidence

Semaglutide may improve Composite of CV death, non-fatal myocardial infarction, or non-fatal stroke.

ConsensusScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The available evidence reports mixed findings.

Ranked evidence signals

1
Composite of CV death, non-fatal myocardial infarction, or non-fatal stroke
EvidenceScore™ Emerging | EvidenceScore™ 47.8 | moderate positive | ConsensusScore™ Mixed | 1 study

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

Only one supporting study is available.
Population details are unavailable.

View Full Evidence

Does Semaglutide improve cardiovascular mortality?

Limited Evidence

Current evidence does not show a clear benefit of Semaglutide for Cardiovascular mortality.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

1
Cardiovascular mortality
EvidenceScore™ Limited | EvidenceScore™ 39.7 | neutral | ConsensusScore™ Consistent | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Population details are unavailable.

View Full Evidence

Does Semaglutide improve nonfatal stroke?

Limited Evidence

Semaglutide may worsen Nonfatal stroke or be associated with harm.

ConsensusScore™: Results are generally consistent across studies.

Ranked evidence signals

1
Nonfatal stroke
EvidenceScore™ Limited | EvidenceScore™ 39.2 | weak negative | ConsensusScore™ Generally Consistent | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, archive views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Cardiovascular Risk Evidence Hub GLP-1 Receptor Agonists Evidence Hub

Explore in archive

Open broader archive views for this relationship.

All studies on Semaglutide and Cardiovascular events All studies on Semaglutide and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)All studies on Semaglutide and All-cause mortality All studies on Semaglutide and Composite of CV death, non-fatal myocardial infarction, or non-fatal stroke

Related research

Read related research summaries.

Oral semaglutide reduces cardiovascular events in type 2 diabetes Higher semaglutide doses improve glucose control in type 2 diabetes Novel Semaglutide Injection Shows Non-Inferior Glycemic Control Oral semaglutide may improve cardiovascular event prevention in type 2 diabetes.Semaglutide cuts insulin needs in adults with type 1 diabetes and obesity

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.